UK Circulating Tumor Cells Market Size & Outlook

The circulating tumor cells market in UK is expected to reach a projected revenue of US$ 1,618.3 million by 2030. A compound annual growth rate of 15.5% is expected of UK circulating tumor cells market from 2025 to 2030.
Revenue, 2024 (US$M)
$698.7
Forecast, 2030 (US$M)
$1,618.3
CAGR, 2025 - 2030
15.5%
Report Coverage
UK

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

UK circulating tumor cells market, 2018-2030 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

UK circulating tumor cells market highlights

  • The UK circulating tumor cells market generated a revenue of USD 698.7 million in 2024 and is expected to reach USD 1,618.3 million by 2030.
  • The UK market is expected to grow at a CAGR of 15.5% from 2025 to 2030.
  • In terms of segment, ctc detection & enrichment methods was the largest revenue generating technology in 2024.
  • CTC Analysis is the most lucrative technology segment registering the fastest growth during the forecast period.

Circulating tumor cells market data book summary

Market revenue in 2024USD 698.7 million
Market revenue in 2030USD 1,618.3 million
Growth rate15.5% (CAGR from 2025 to 2030)
Largest segmentCtc detection & enrichment methods
Fastest growing segmentCTC Analysis
Historical data2018 - 2023
Base year2024
Forecast period2025 - 2030
Quantitative unitsRevenue in USD million
Market segmentationCTC Detection & Enrichment Methods, CTC Direct Detection Methods, CTC Analysis
Key market players worldwideQiagen NV, Bio-Techne Corp, Praxis Precision Medicines Inc Ordinary Shares, Aviva PLC, Biocept Inc, Neurocrine Biosciences Inc, Greiner Bio-One, Miltenyi Biotec, Icon PLC, Ecolab Inc, Arcus Biosciences Inc, Epic Corp, Screen Holdings Co Ltd, Menarini Group, Vtex Ordinary Shares - Class A, Sysmex Corp, STEMCELL Technologies

Other key industry trends

  • In terms of revenue, UK accounted for 5.5% of the global circulating tumor cells market in 2024.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Europe, Germany circulating tumor cells market is projected to lead the regional market in terms of revenue in 2030.
  • UK is the fastest growing regional market in Europe and is projected to reach USD 1,618.3 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Circulating Tumor Cells Market Companies

Name Profile # Employees HQ Website
Vtex Ordinary Shares - Class A View profile 1277 125 Kingsway, Aviation House, London, United Kingdom, WC2B 6NH https://www.vtex.com
Arcus Biosciences Inc View profile 577 3928 Point Eden Way, Hayward, CA, United States, 94545 https://www.arcusbio.com
Neurocrine Biosciences Inc View profile 1448 12780 El Camino Real, San Diego, CA, United States, 92130 https://www.neurocrine.com
Praxis Precision Medicines Inc Ordinary Shares View profile 82 99 High Street, 30th Floor, Boston, MA, United States, 02110 https://www.praxismedicines.com
STEMCELL Technologies View profile 501-1000 Vancouver, British Columbia, Canada, North America https://www.stemcell.com
Menarini Group View profile 1001-5000 Firenze, Toscana, Italy, Europe http://www.menarini.com
Greiner Bio-One View profile 1001-5000 Monroe, North Carolina, United States, North America https://www.gbo.com/en_US/
Ecolab Inc View profile 48000 1 Ecolab Place, Saint Paul, MN, United States, 55102 https://www.ecolab.com
Aviva PLC View profile 23247 St Helen's, 1 Undershaft, London, United Kingdom, EC3P 3DQ https://www.aviva.com
Screen Holdings Co Ltd View profile 6589 Tenjinkita-machi 1-1, Teranouchi-agaru, 4-chome, Horikawa-dori, Kamigyo-ku, Kyoto, Japan, 602-8585 https://www.screen.co.jp
Miltenyi Biotec View profile 1001-5000 Bergisch Gladbach, Nordrhein-Westfalen, Germany, Europe http://www.miltenyibiotec.com
Icon PLC View profile 41150 South County Business Park, Leopardstown, Dublin, Ireland, D18 X5R3 https://www.iconplc.com
Bio-Techne Corp View profile 3050 614 McKinley Place N.E., Minneapolis, MN, United States, 55413 https://www.bio-techne.com
Sysmex Corp View profile 10448 1-5-1 Wakinohara-Kaigandori, Chuo-ku, Hyogo Prefecture, Kobe, Japan, 6510073 http://www.sysmex.co.jp
Biocept Inc View profile 50 9955 Mesa Rim Road, San Diego, CA, United States, 92121 https://www.biocept.com
Qiagen NV View profile 5900 Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL https://www.qiagen.com
Epic Corp View profile 2 PO Box 11147, Newport Beach, CA, United States, 92658

UK circulating tumor cells market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to circulating tumor cells market will help companies and investors design strategic landscapes.


Ctc detection & enrichment methods was the largest segment with a revenue share of 56.76% in 2024. Horizon Databook has segmented the UK circulating tumor cells market based on ctc detection & enrichment methods, ctc direct detection methods, ctc analysis covering the revenue growth of each sub-segment from 2018 to 2030.


The UK is considered to be a good entry point to Europe for branded generic manufacturers. This can be attributed to factors such as high generics penetration (approximately 70% by volume), low entry barriers, and relatively simplified entry requirements.

However, sustaining in the UK market can be difficult for branded generics players, as there is high dominance of unbranded generics in the UK market. This impedes the opportunity to differentiate by company brand or product; thereby, manufacturers are mainly dependent on pricing.

Moreover, physicians are mandated to prescribe according to International Nonproprietary Name (INN) in the UK. However, according to a research study, around 82% of all prescriptions are prescribed according to INN, which could slow down the branded generics growth compared to unbranded generics.

Reasons to subscribe to UK circulating tumor cells market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of UK circulating tumor cells market databook

  • Our clientele includes a mix of circulating tumor cells market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the UK circulating tumor cells market , including forecasts for subscribers. This country databook contains high-level insights into UK circulating tumor cells market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

UK circulating tumor cells market size, by technology, 2018-2030 (US$M)

UK Circulating Tumor Cells Market Outlook Share, 2024 & 2030 (US$M)

UK circulating tumor cells market size, by technology, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online